Introducing Mounjaro: A Once-Weekly, First-in-Class GIP and GLP-1 Receptor Agonist

0 SAR
Checkout

Overview

Introducing Mounjaro, understand its mechanism of action, why patients like Manar struggle to lose weight and maintain and the role of GIP and GLP-1






Disclaimer

This content is approved by Eli Lilly and Company (“Lilly”). This content is intellectual property of Lilly and its reproduction needs Lilly's prior permission
(This information/content is intended to Health Care Providers only)

For adverse events and safety reporting: email: saudi_pharmacovigilance@lilly.com
24 /7 mobile : +966 567 868 843 working hours: +966 11 461 7800 , Ext: 1
For Lilly product information: email: SAUDI_MEDINFOQUERIES@lilly.com
For further information, please contact:
Eli Lilly and Company, Scientific Office P.O. Box 92120 Riyadh 11653, Kingdom of Saudi Arabia. Tel: +966 11 461 7800 Fax: +966 111 217 9900 email: Saudi_Pharmacovigilance@lilly.com

Please go to PDF Material for prescribing information


PP-TR-SA-0381

This Class for

  • Clinical Pharmacy
  • Pharmacy
  • Physician
  • Resident / Fellow

What I will learn?

  • .

Related Classes